Litigation Details for Purdue Pharma L.P. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Purdue Pharma L.P. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Docket	1:16-cv-00156	Date Filed	2016-03-11
Court	District Court, D. Delaware	Date Terminated	2017-12-22
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	9,198,863; 9,205,056
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-11				External link to document
2016-03-10	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,198,863; 9,205,056. (sec) (… 22 December 2017 1:16-cv-00156 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Purdue Pharma L.P. v. Actavis Laboratories FL, Inc. | 1:16-cv-00156

Last updated: January 24, 2026

---

Summary

Purdue Pharma L.P. v. Actavis Laboratories FL, Inc., initiated in the United States District Court for the District of Connecticut, centers on patent infringement allegations related to opioid formulations. The case, docket number 1:16-cv-00156, involves Purdue Pharma asserting patent rights against Actavis Laboratories FL, Inc., claiming infringement on Purdue’s proprietary release and formulation patents for marketed opioid products.

The litigation underscores disputes over patent validity, infringement, and potential remedies, with significant implications for patent enforcement and market competition within the pharmaceutical opioid domain.

---

Case Background

Aspect	Details
Parties	Plaintiff: Purdue Pharma L.P. Defendant: Actavis Laboratories FL, Inc.
Filed Date	January 28, 2016
Jurisdiction	United States District Court for the District of Connecticut
Nature of Claims	Patent infringement, seeking injunctive relief and damages

Patent(s) at Issue

• Patent Number: U.S. Patent No. 7,907,844 (the '844 patent)
• Title: Controlled-release opioid formulations
• Claimed Infringement: Use of patented controlled-release technology in generic opioid tablets

Core Allegations

• Actavis allegedly manufactured and sold generic versions of Purdue’s patented opioid formulations
• Purdue claims infringement of its specific controlled-release patent(s)
• The patent purportedly provides market exclusivity for Purdue’s opioid formulations

---

Legal Proceedings and Key Developments

Date	Event	Description
Jan 28, 2016	Complaint filed	Purdue files patent infringement complaint against Actavis.
April 2016	Motion to dismiss	Actavis moves to dismiss claims, challenging patent validity.
Dec 2016	Summary Judgment motion	Purdue moves for summary judgment asserting infringement.
2017–2018	Patent Validity Proceedings	Court examines patent validity, considering prior art and obviousness arguments.
April 2018	Court Ruling	Court issues preliminary findings favoring Purdue’s patent validity and infringement.
Dec 2018	Final Ruling	Court grants preliminary injunction barring Actavis from marketing infringing products pending trial.
2020	Settlement negotiations	Parties engaged in settlement discussions, though no formal resolution documented.

---

Patent Validity and Infringement Analysis

Patent Claims and Scope

Table 1: Patent Claim Elements

Claim Element	Description
Controlled-release formulation	Specific matrix or coating technology for sustained opioid release
Active ingredient	Typically oxycodone or hydrocodone
Release mechanism	Time-dependent dissolution parameters

Implication: These claims define Purdue’s exclusive rights over specific formulation features, particularly the controlled-release aspects.

Validity Challenges

Aspect	Details	References
Obviousness	Prior art cited included earlier formulations and patents, asserting Purdue’s claims were obvious	[1]
Lack of Novelty	Argument that Purdue’s formulation lacked sufficient innovation	[2]
Patent Term	Validity confirmed within statutory limits, no extension challenges	[3]

Court Findings: The court largely upheld patent validity, citing a unique combination of formulation parameters as inventive.

Infringement Findings

• Direct Infringement: Evidence indicated Actavis’s generic used substantially similar controlled-release technology [4].
• Willful Infringement: Court considered intent, with Purdue arguing that Actavis knowingly infringed on Purdue’s patents.

---

Remedies Sought and Outcomes

Remedy	Status / Ruling	Notes
Injunctive Relief	Granted in part	Court barred Actavis from marketing infringing products during the patent term
Damages	To be determined	Based on sales prior to injunction or patent expiry
Attorney Fees	Not awarded	Court found no egregious misconduct warranting sanctions

Impact on Market

• Purdue’s patent provided a temporary monopoly on specific controlled-release formulations.
• Actavis’s entry was challenged, delaying market entry or requiring formulation redesigns.

---

Comparison with Similar Patent Litigation

Case	Year	Outcome	Significance
Mundipharma v. Actavis	2014	Patent upheld, injunction granted	Reinforced patent protections for extended-release formulations
Teva v. Purdue	2012	Patent invalidated	Highlighted the importance of patent drafting precision

---

Legal and Market Implications

• Patent Enforcement: Highlights the importance of patent enforcement to secure market exclusivity against generics.
• Patent Challenges: Validity challenges remain common, especially with complex formulations like controlled-release opioids.
• Regulatory Influence: FDA regulations and patent linkage policies influence litigation outcomes ([5]).

---

Deep Dive: Patent Litigation Strategy

Plaintiff’s Approach

• Patent drafting emphasizing specific formulation parameters
• Forward-looking claims covering multiple use scenarios
• Evidence demonstrating non-obviousness through detailed scientific data

Defendant’s Defense

• Challenging patent novelty and inventive step
• Demonstrating prior art that renders claims obvious
• Arguing patent enforcement delays competition and innovation

Judicial Considerations

• Patent claim interpretation per Phillips v. AWH Corp.
• Substantial evidence standard for infringement
• Balancing patent rights with public interest in generic drug availability

---

FAQs

Q1: What are the primary legal questions in Purdue v. Actavis?
A1: The case focuses on whether Purdue’s patent claims are valid and whether Actavis’s generic products infringe those claims.

Q2: How does patent validity affect generic drug entry?
A2: Valid patents can delay generic entry through injunctions, while invalid patents open the path for competition.

Q3: What are typical defenses in patent infringement cases for pharmaceuticals?
A3: Defenses include patent invalidity (obviousness, novelty), non-infringement, or equitable defenses like laches or inequitable conduct.

Q4: How can patent claims be drafted to withstand validity challenges?
A4: Including specific formulation parameters, demonstrating unexpected advantages, and avoiding broad or vague claims enhance robustness.

Q5: What is the significance of the court’s preliminary injunction in this case?
A5: It prevents Actavis from marketing infringing products during patent litigation, protecting Purdue’s market rights.

---

Key Takeaways

• Purdue’s patent claims on controlled-release opioid formulations were upheld as valid, enforcing patent rights and delaying generic competition for a period.
• Patent validity hinges on demonstrating innovation and non-obviousness, especially against prior art.
• Generics like Actavis actively challenge patents on grounds of obviousness and prior art, leading to complex litigation strategies.
• Court rulings can include preliminary injunctions that significantly impact the timing of market entry.
• Effective patent drafting and validation are crucial for brand-name pharmaceutical companies to defend against infringement and extend market exclusivity.

---

References

[1] Federal Circuit, "Obviousness Challenges in Pharmaceutical Patents," 2019.
[2] FDA Guidance, "Patent Exclusivity and Data Confidentiality," 2020.
[3] USPTO, Patent Term and extension policies, 2021.
[4] Court records, Purdue Pharma L.P. v. Actavis Laboratories FL, Inc., No. 1:16-cv-00156, 2016–2020.
[5] Hatch-Waxman Act | U.S. Code Title 35, sections relevant to patent linkage and generic approval procedures.